GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score

The GALAD score is a serum biomarker-based model that predicts the probability of having hepatocellular carcinoma (HCC) in patients with chronic liver disease. We aimed to assess the performance of the GALAD score in comparison with liver ultrasound for detection of HCC. A single-center cohort of 11...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer epidemiology, biomarkers & prevention biomarkers & prevention, 2019-03, Vol.28 (3), p.531-538
Hauptverfasser: Yang, Ju Dong, Addissie, Benyam D, Mara, Kristin C, Harmsen, William S, Dai, Jianliang, Zhang, Ning, Wongjarupong, Nicha, Ali, Hawa M, Ali, Hamdi A, Hassan, Fatima A, Lavu, Sravanthi, Cvinar, Jessica L, Giama, Nasra H, Moser, Catherine D, Miyabe, Katsuyuki, Allotey, Loretta K, Algeciras-Schimnich, Alicia, Theobald, J Paul, Ward, Melissa M, Nguyen, Mindie H, Befeler, Alex S, Reddy, K Rajender, Schwartz, Myron, Harnois, Denise M, Yamada, Hiroyuki, Srivastava, Sudhir, Rinaudo, Jo Ann, Gores, Gregory J, Feng, Ziding, Marrero, Jorge A, Roberts, Lewis R
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The GALAD score is a serum biomarker-based model that predicts the probability of having hepatocellular carcinoma (HCC) in patients with chronic liver disease. We aimed to assess the performance of the GALAD score in comparison with liver ultrasound for detection of HCC. A single-center cohort of 111 HCC patients and 180 controls with cirrhosis or chronic hepatitis B and a multicenter cohort of 233 early HCC and 412 cirrhosis patients from the Early Detection Research Network (EDRN) phase II HCC Study were analyzed. The area under the ROC curve (AUC) of the GALAD score for HCC detection was 0.95 [95% confidence interval (CI), 0.93-97], which was higher than the AUC of ultrasound (0.82,
ISSN:1055-9965
1538-7755
DOI:10.1158/1055-9965.EPI-18-0281